Dual-targeted therapy with pyrotinib and trastuzumab for HER2-positive advanced colorectal cancer: Preliminary results from a multicenter phase 2 trial.
Ying Yuan(Zhejiang Cancer Hospital), Suzhan Zhang(Zhejiang Cancer Hospital), Weidong Han(Chinese PLA General Hospital), Xianhua Fu(Zhejiang University), Liu Yang(Mudanjiang Medical University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Weijia Fang(Zhejiang Cancer Hospital)
Cited by 10
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
IGF2BP2 regulates DANCR by serving as an N6-methyladenosine reader
|Cell Death and Differentiation|2019|424
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417